Neoplastic Disease

发表于：Archives of Internal Medicine · 年份：1965 · DOI：10.1001/archinte.1965.03870060044010 · 被引用次数：12 · 研究领域：Childhood Cancer Survivors' Quality of Life、Occupational and environmental lung diseases、Multiple and Secondary Primary Cancers

ONE OF THE most important advances in clinical cancer chemotherapy in recent years has been the demonstration that products of the periwinkle plantVinca roseaLinn. have antitumor activity in patients with neoplastic disease.1Vinblastine has been effective in patients with Hodgkin's disease and lymphosarcoma.2,3There is also evidence for some degree of antitumor activity in a variety of solid tumors, particularly carcinoma of the breast, but the extent of this effect is not clear.1The Eastern Cooperative Group in Solid Tumor Chemotherapy undertook preliminary studies of vinblastine in 1961. Dose response studies indicated that for the majority of patients 0.3 mg/kg was well tolerated, producing in most of the patients mild to moderate, reversible myelosuppression.3Because occasionally a patient had myelosuppression with smaller doses, it was proposed that the doses employed in the therapeutic trial start at 0.1 mg/kg/week and be increased by 0.1 mg/kg/week to a maximum of